These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35807373)

  • 1. Quantitative Determination of Four Potential Genotoxic Impurities in the Active Pharmaceutical Ingredients in TSD-1 Using UPLC-MS/MS.
    Wang T; Yang H; Yang J; Guo N; Wu G; Xu X; An M
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective and sensitive UPLC-MS/MS approach for trace level quantification of four potential genotoxic impurities in zolmitriptan drug substance.
    Vijaya Bhaskar Reddy A; Venugopal N; Madhavi G; Gangadhara Reddy K; Madhavi V
    J Pharm Biomed Anal; 2013 Oct; 84():84-9. PubMed ID: 23816589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous and trace level quantification of two potential genotoxic impurities in valsartan drug substance using UPLC-MS/MS.
    Li S; Dong L; Tang K; Lan Z; Liu R; Wang Y; Wang R; Lin H
    J Pharm Biomed Anal; 2022 Apr; 212():114630. PubMed ID: 35158183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple and sensitive LC-MS/MS method for determination and quantification of potential genotoxic impurities in the ceritinib active pharmaceutical ingredient.
    Antolčić M; Runje M; Galić N
    Anal Methods; 2020 Jul; 12(25):3290-3295. PubMed ID: 32930193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of an analytical method for quantitative determination of three potentially genotoxic impurities in vildagliptin drug material using HPLC-MS.
    Al-Sabti B; Harbali J
    J Sep Sci; 2021 Jul; 44(13):2587-2595. PubMed ID: 33934507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPLC-MS Analysis of Four Potential Genotoxic Impurities in Alogliptin Pharmaceutical Materials.
    Al-Sabti B; Harbali J
    J AOAC Int; 2022 Mar; 105(2):362-369. PubMed ID: 34849990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UHPLC-MS/MS Method Development and Validation for the Genotoxic Impurities Trimethyl Phosphate and Triisopropyl Phosphate of Elagolix Sodium.
    Hao Y; Feng Z; Zhuang X; Teng H; Zhang G
    J Chromatogr Sci; 2024 Feb; 62(2):140-146. PubMed ID: 37207323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The determination of two analogues of 4-(azidomethyl)-1,1'-biphenyl as potential genotoxic impurities in the active pharmaceutical ingredient of several sartans containing a tetrazole group.
    Jireš J; Gibala P; Kalášek S; Douša M; Doubský J
    J Pharm Biomed Anal; 2021 Oct; 205():114300. PubMed ID: 34365191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Sensitive GC-MS/MS Method for the Determination of Five Potential Genotoxic Impurities in Abiraterone Acetate.
    Zhong Z; Chen Y; Xia H; Chen Z; Cheng Q
    J Chromatogr Sci; 2022 Feb; 60(2):105-110. PubMed ID: 34059885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of potential genotoxic impurities in rabeprazole active pharmaceutical ingredient via Liquid Chromatography-tandem Mass Spectrometry, following quality-by-design principles for method development.
    Iliou K; Malenović A; Loukas YL; Dotsikas Y
    J Pharm Biomed Anal; 2018 Feb; 149():410-418. PubMed ID: 29154196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a selective, sensitive and stability indicating UPLC-MS/MS method for rapid, simultaneous determination of six process related impurities in darunavir drug substance.
    A VBR; Yusop Z; Jaafar J; Aris AB; Majid ZA; Umar K; Talib J
    J Pharm Biomed Anal; 2016 Sep; 128():141-148. PubMed ID: 27262107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a systematic UPLC-MS/MS method for simultaneous determination of three phenol impurities in ritonavir.
    Venugopal N; Vijaya Bhaskar Reddy A; Madhavi G
    J Pharm Biomed Anal; 2014 Mar; 90():127-33. PubMed ID: 24366213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UPLC-ESI/Q-TOF MS/MS Method for Determination of Vildagliptin and its Organic Impurities.
    Ferrazza Alves Giordani C; Campanharo S; Ribeiro Wingert N; Maronesi Bueno L; Wittckind Manoel J; Virginia Garcia C; Maria Volpato N; Dineck Iop G; de Azevedo Mello P; Marlon de Moraes Flores E; Eva Scherman Schapoval E; Steppe M
    J Chromatogr Sci; 2020 Aug; 58(8):718-725. PubMed ID: 32705127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a stability-indicating UPLC method for determining olanzapine and its associated degradation products present in active pharmaceutical ingredients and pharmaceutical dosage forms.
    Krishnaiah Ch; Vishnu Murthy M; Kumar R; Mukkanti K
    J Pharm Biomed Anal; 2011 Mar; 54(4):667-73. PubMed ID: 21075576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Method for trace determination of N-nitrosamines impurities in metronidazole benzoate using high-performance liquid chromatography coupled with atmospheric-pressure chemical ionization tandem mass spectrometry.
    Yin M; Hu Y; Fan H; Wang Q; Wang M; Wang W; Shi C
    J Sep Sci; 2023 Mar; 46(5):e2200225. PubMed ID: 36562102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UPLC and LC-MS studies on degradation behavior of irinotecan hydrochloride and development of a validated stability-indicating ultra-performance liquid chromatographic method for determination of irinotecan hydrochloride and its impurities in pharmaceutical dosage forms.
    Kumar N; Sangeetha D; Reddy SP
    J Chromatogr Sci; 2012 Oct; 50(9):810-9. PubMed ID: 22661461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of ultra-performance liquid chromatography method for the determination of meloxicam and its impurities in active pharmaceutical ingredients.
    Louati K; Bargaoui I; Safta F
    Ann Pharm Fr; 2018 May; 76(3):187-200. PubMed ID: 29544974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of potentially genotoxic impurities in crotamiton active pharmaceutical ingredient by gas chromatography.
    Kalauz A; Kapui I
    J Pharm Biomed Anal; 2022 Feb; 210():114544. PubMed ID: 34968997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.